Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)
23 December 2014 - 7:11AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the
U.S. Food and Drug Administration (FDA) has approved Opdivo
(nivolumab).
Please see full Prescribing Information available at
www.bms.com.
The company will provide additional details on the approval in a
press release to follow.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global pharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit www.bms.com, or
follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers Squibb CompanyMedia:Sarah Koenig,
609-252-4145sarah.koenig@bms.comorCarrie Fernandez,
609-419-5448carrie.fernandez@bms.comorChristina Trank,
609-419-5497christina.trank@bms.comorInvestors:John Elicker,
609-252-4611john.elicker@bms.comorRanya Dajani,
609-252-5330ranya.dajani@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024